( WORCESTER MA - May 24 2007 - Generex...)Generex Biotechnology Vaccine Strategy Presented at International,Conference in London,Health

WORCESTER, MA - May 24, 2007 - Generex Biotechnology Corporation (NasdaqCM:GNBT) announced today that Dr. Douglas Powell, Director of Immunobiology at its wholly-owned Antigen Express subsidiary, has presented Antigen's vaccine development strategy at an international conference in London, UK. The international meeting, "Developing New Anti-Infective Agents - Challenges and Opportunities" (www.anti-infectives-forum.com), is being held May 24th and 25th and brings together leading individuals from academia, industry, and regulatory agencies.

The focus of Dr. Powell's presentation was the immunogenicity of proprietary peptide vaccines being developed by Antigen Express, both when used alone and in combination with other types of vaccines. The Company is currently conducting a Phase II clinical trial of one of its peptides in breast cancer patients and a Phase I trial in volunteers of other peptides for the potentially pandemic H5N1 avian influenza. In both of these disease areas, cancer and avian influenza, novel forms of immunotherapy and vaccine are clearly needed.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMistT device. The Company's flagship product, oral insulin (Generex Oral-lynT), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core p
'"/>